Cargando…

Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity

Tumor progression is facilitated immunologically by mechanisms that include low antigen expression, an absence of coimmunostimulatory signals, and the presence of regulatory T cells (Tregs), all of which act to suppress and restrict effector T cells in the tumor. It may be possible to overcome these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villarreal, Daniel O., Chin, Diana, Smith, Melissa A., Luistro, Leopoldo L., Snyder, Linda A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503599/ https://www.ncbi.nlm.nih.gov/pubmed/28388572 http://dx.doi.org/10.18632/oncotarget.16605

Ejemplares similares

Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment
por: Villarreal, Daniel O., et al.
Publicado: (2017)

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
por: Lu, Lei, et al.
Publicado: (2014)

Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism
por: Patel, Jaina M., et al.
Publicado: (2019)

An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
por: Chan, Sarah, et al.
Publicado: (2022)

Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness
por: Hirschhorn, Daniel, et al.
Publicado: (2021)

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity
por: Liu, Huisi, et al.
Publicado: (2022)

Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery
por: Narumi, Kenta, et al.
Publicado: (2019)

CD8(+) T Cells: GITR Matters
por: Ronchetti, Simona, et al.
Publicado: (2012)

Glucocorticoid-Induced TNFR-Related (GITR) Protein and Its Ligand in Antitumor Immunity: Functional Role and Therapeutic Modulation
por: Placke, Theresa, et al.
Publicado: (2010)

The Role of GITR/GITRL Interaction in Autoimmune Diseases
por: Tian, Jie, et al.
Publicado: (2020)

Targeting GITR in cancer immunotherapy – there is no perfect knowledge
por: Davar, Diwakar, et al.
Publicado: (2023)

Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment
por: Nair-Gupta, Priyanka, et al.
Publicado: (2020)

Murine B Cell Development and Antibody Responses to Model Antigens Are Not Impaired in the Absence of the TNF Receptor GITR
por: Sinik Teodorovic, Lenka, et al.
Publicado: (2012)

Development of a fully human anti‐GITR antibody with potent antitumor activity using H2L2 mice
por: Tong, Qiuli, et al.
Publicado: (2022)

Pharmacodynamic analysis of an agonistic antibody to the costimulatory receptor GITR
por: Moody, Gordon, et al.
Publicado: (2015)

The role of GITR single‐positive cells in immune homeostasis
por: Nocentini, Giuseppe, et al.
Publicado: (2017)

New emerging targets in cancer immunotherapy: the role of GITR
por: Buzzatti, Giulia, et al.
Publicado: (2020)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
por: Xu-Monette, Zijun Y., et al.
Publicado: (2017)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity
por: Zhang, Yuankun, et al.
Publicado: (2023)

GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T Cells
por: Rakké, Yannick S., et al.
Publicado: (2022)

Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib
por: Zhao, Yinghao, et al.
Publicado: (2015)

GITR-GITRL System, A Novel Player in Shock and Inflammation
por: Krausz, Ludovic Tibor, et al.
Publicado: (2007)

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice
por: Qin, Wan, et al.
Publicado: (2020)

Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein
por: Morillon, Y. Maurice, et al.
Publicado: (2017)

GITR ligation enhances functionality of tumor‐infiltrating T cells in hepatocellular carcinoma
por: van Beek, Adriaan A., et al.
Publicado: (2019)

T‐cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer
por: Liu, Jian‐Feng, et al.
Publicado: (2017)

Multiple mechanisms for TRAF3-mediated regulation of the T cell costimulatory receptor GITR
por: Li, Hanzeng, et al.
Publicado: (2021)

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
por: Ye, Jian, et al.
Publicado: (2023)

In vitro up-regulation of expression of GITR on human CD8+ cells
por: Thanavala, Yasmin
Publicado: (2009)

GITR Activation Positively Regulates Immune Responses against Toxoplasma gondii
por: Costa, Frederico R. C., et al.
Publicado: (2016)

PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
por: Li, Yuan, et al.
Publicado: (2018)

Quantitative systems pharmacology model of GITR‐mediated T cell dynamics in tumor microenvironment
por: Ji, Yan, et al.
Publicado: (2023)

Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immunome evaluation
por: You, Wenjie, et al.
Publicado: (2020)

Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer
por: Ma, Yangyang, et al.
Publicado: (2023)

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
por: Lewis, Katherine E., et al.
Publicado: (2017)

Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
por: Yadavilli, Sapna, et al.
Publicado: (2023)

Polyamine blockade promotes antitumor immunity
por: Hayes, Candace S, et al.
Publicado: (2014)

GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory
por: Durham, Nick M., et al.
Publicado: (2017)

Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model
por: Yamaguchi, Izumi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9u8ae9niqo1dfr04u3mgfa9uof